Literature DB >> 16124034

Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis.

Russell J Mortishire-Smith1, Desmond O'Connor, Jose M Castro-Perez, Jane Kirby.   

Abstract

The resource investment required to characterise the metabolic fate of a compound is relatively large, meaning that within a drug discovery environment relatively few compounds are characterised in depth. Rate-limiting steps include the setting up of a complex array of mass spectrometry experiments and the subsequent analysis of the large data sets produced. We describe here a strategy for the evaluation of metabolic routes using full-scan high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry (LC/QToFMS) with automated data analysis using Metabolynx, a commercially available software package. Data from several structurally diverse compounds taken from the literature illustrate that, with careful setting of key parameters, this approach is able to indicate the presence of a wide range of metabolites with only a limited requirement for manual intervention. Copyright (c) 2005 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2005        PMID: 16124034     DOI: 10.1002/rcm.2111

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  14 in total

Review 1.  Xenobiotic metabolism: a view through the metabolometer.

Authors:  Andrew D Patterson; Frank J Gonzalez; Jeffrey R Idle
Journal:  Chem Res Toxicol       Date:  2010-05-17       Impact factor: 3.739

2.  A comprehensive investigation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) metabolism in the mouse using a multivariate data analysis approach.

Authors:  Chi Chen; Xiaochao Ma; Michael A Malfatti; Kristopher W Krausz; Shioko Kimura; James S Felton; Jeffrey R Idle; Frank J Gonzalez
Journal:  Chem Res Toxicol       Date:  2007-02-06       Impact factor: 3.739

3.  Post-acquisition data processing for the screening of transformation products of different organic contaminants. Two-year monitoring of river water using LC-ESI-QTOF-MS and GCxGC-EI-TOF-MS.

Authors:  S Herrera López; M M Ulaszewska; M D Hernando; M J Martínez Bueno; M J Gómez; A R Fernández-Alba
Journal:  Environ Sci Pollut Res Int       Date:  2014-06-22       Impact factor: 4.223

Review 4.  Drug metabolite profiling and identification by high-resolution mass spectrometry.

Authors:  Mingshe Zhu; Haiying Zhang; W Griffith Humphreys
Journal:  J Biol Chem       Date:  2011-06-01       Impact factor: 5.157

5.  A Simple, Rapid and Reliable Method to Determine Imipramine and Desipramine in Mouse Serum Using Ultra-High-Performance Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry.

Authors:  Jing Zhao; Yujin Shin; Kwang-Hoon Chun; Hye-Ran Yoon; Jeongmi Lee
Journal:  J Chromatogr Sci       Date:  2015-12-19       Impact factor: 1.618

Review 6.  High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites.

Authors:  M Holcapek; L Kolárová; M Nobilis
Journal:  Anal Bioanal Chem       Date:  2008-03-15       Impact factor: 4.142

Review 7.  LC-MS-based metabolomics in drug metabolism.

Authors:  Chi Chen; Frank J Gonzalez; Jeffrey R Idle
Journal:  Drug Metab Rev       Date:  2007       Impact factor: 4.518

Review 8.  Analytical tools and approaches for metabolite identification in early drug discovery.

Authors:  Yuan Chen; Mario Monshouwer; William L Fitch
Journal:  Pharm Res       Date:  2006-10-18       Impact factor: 4.580

9.  Advances in structure elucidation of small molecules using mass spectrometry.

Authors:  Tobias Kind; Oliver Fiehn
Journal:  Bioanal Rev       Date:  2010-08-21

10.  Profiling of hepatic clearance pathways of Pittsburgh compound B and human liver cytochrome p450 phenotyping.

Authors:  Anne Van Vlaslaer; Russell J Mortishire-Smith; Claire Mackie; Xavier Langlois; Mark E Schmidt
Journal:  EJNMMI Res       Date:  2013-02-14       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.